SAB Biotherapeutics, Inc. (SABS) has a MoatMap StockRank of 70/100 based on Quality (51/100), Value (42/100), and Momentum (58/100) factor scores. The current signal is BUY. SAB Biotherapeutics is a small biotech company. Its quality score of 54 is insufficient for high conviction, as biotech often involves speculative R&D, binary outcomes, and lacks consistent FCF, making it incompatible with the quality compounder philosophy.